SCHEMBL8809115

SCHEMBL8809115

CCOC(=O)c1cc2ccc3c(c2cc1O)OC(n1cccc1)=C(C#N)C3c1ccc2c(c1)OCO2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.42
▸ MAPT P10636 8/20 0.42
▸ KDM4E B2RXH2 5/20 0.42
▸ POLB P06746 5/20 0.42
▸ HPGD P15428 4/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ GAA P10253 4/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ CASP1 P29466 2/20 0.42
▸ HTT P42858 2/20 0.42
▸ HSD17B10 Q99714 3/20 0.42
▸ TSHR P16473 1/20 0.42
▸ LMNA P02545 1/20 0.39
▸ CSNK2B P67870 1/20 0.39
▸ CSNK2A1 P68400 1/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ F2 P00734 1/20 0.38
▸ RCE1 Q9Y256 1/20 0.38
▸ USP2 O75604 1/20 0.36
▸ ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8808977 0.88 MAPT (0.53) ALDH1A1MAPTKDM4EPOLBHPGD
SCHEMBL8811063 0.87 MYB (0.38) ALDH1A1MAPTKDM4EHPGDKMT2A
SCHEMBL8810581 0.87 MYB (0.48) MAPTKDM4EPOLBHPGDKMT2A
SCHEMBL8811837 0.84 MYB (0.48) ALDH1A1MAPTPOLBKMT2AMEN1
SCHEMBL8807532 0.84 MEN1 (0.46) ALDH1A1MAPTKDM4EHPGDKMT2A
SCHEMBL8808545 0.79 CYP1A2 (0.54) ALDH1A1MAPTPOLBHPGDKMT2A
SCHEMBL8809139 0.76 MYB (0.47) ALDH1A1MAPTPOLBKMT2AMEN1
SCHEMBL8808745 0.75 MYB (0.49) ALDH1A1MAPTKDM4EHPGDKMT2A
SCHEMBL8808823 0.74 MYB (0.50) ALDH1A1MAPTKDM4EPOLBKMT2A
SCHEMBL8810573 0.74 MYB (0.61) MAPTKDM4EPOLBHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5574034-A TREATMENT OF IMMUNE DISEASES AND EXCESS CELL PROLIFERATION, ENZYME INHIBITORS ELI LILLY AND COMPANY (US) 1996-11-12 — — US claimed
EP-0618206-B1 Pharmaceutical compounds LILLY INDUSTRIES LTD (GB) 1997-09-17 — — EP disclosed
US-5576325-A TREATMENT OF IMMUNE DISEASES, RESTENOSIS, ENZYME INHIBITORS AND ANTISPASMODIC AGENTS LILLY INDUSTRIES LIMITED (GB) 1996-11-19 — — US disclosed
US-5574034-A TREATMENT OF IMMUNE DISEASES AND EXCESS CELL PROLIFERATION, ENZYME INHIBITORS ELI LILLY AND COMPANY (US) 1996-11-12 — — US disclosed
US-5571818-A FOR TREATING IMMUNE DISEASES OR A DISEASE IN WHICH EXCESS CELL PROLIFERATION OR ENZYME RELEASE OCCUR ELI LILLY AND COMPANY (US) 1996-11-05 — — US disclosed
US-5514699-A Pharmaceutical compounds LILLY INDUSTRIES LIMITED (GB) 1996-05-07 — — US disclosed
EP-0618206-A1 Pharmaceutical compounds LILLY INDUSTRIES LIMITED (GB) 1994-10-05 — — EP disclosed
Send feedback